Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 1c ; Offers Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $74.38 million versus the consensus estimate of $74.2 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2025 revenue of $285-290 million, versus the consensus of $286.5 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• The DICK'S Sporting Goods Foundation Quarterly Giving Series: Q2 2026
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'